Funds › RTW Investments, LP
RTW Investments, LP
13F for Q2 2026, filed Aug 14, 2026. 84 positions worth $11.7B.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q2 2026
filed Aug 14, 2026
Reported value
$11.7B
+$1.7B (16.5%) vs Q1 2026
Positions
84
88 in Q1 2026
Top 10 share
47.7%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of RTW Investments, LP in the latest 13F quarter?
Using 13F.ai, how has RTW Investments, LP's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of RTW Investments, LP's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | MDGL Madrigal Pharmaceuticals, Inc. | 1.99M | $1.1B | 9.1% | Unchanged | 13F ↗ |
| 2 | ARGX argenx SE · ADR | 709,446 | $658.2M | 5.6% | Unchanged | 13F ↗ |
| 3 | PTCT PTC Therapeutics, Inc. | 7.75M | $631.9M | 5.4% | Unchanged | 13F ↗ |
| 4 | PTGX Protagonist Therapeutics, Inc. | 5.06M | $620.4M | 5.3% | Unchanged | 13F ↗ |
| 5 | CGON CG Oncology, Inc. | 8.51M | $605.0M | 5.2% | +21.9% | 13F ↗ |
| 6 | INSM Insmed Incorporated · Com Par $.01 | 4.84M | $516.3M | 4.4% | Unchanged | 13F ↗ |
| 7 | TNGX Tango Therapeutics, Inc. | 13.90M | $434.5M | 3.7% | +4.5% | 13F ↗ |
| 8 | SYRE Spyre Therapeutics, Inc. | 4.25M | $377.5M | 3.2% | +1.9% | 13F ↗ |
| 9 | CELC Celcuity Inc. | 3.30M | $345.8M | 3.0% | +8.7% | 13F ↗ |
| 10 | ERAS Erasca, Inc. | 17.95M | $328.8M | 2.8% | +11.1% | 13F ↗ |
| 11 | RDNT RadNet, Inc. | 4.85M | $298.9M | 2.6% | +13.1% | 13F ↗ |
| 12 | ORKA Oruka Therapeutics, Inc. | 3.14M | $298.7M | 2.6% | +52.5% | 13F ↗ |
| 13 | NTRA Natera, Inc. | 1.00M | $271.4M | 2.3% | -20.0% | 13F ↗ |
| 14 | RARE Ultragenyx Pharmaceutical Inc. | 7.80M | $260.3M | 2.2% | +114% | 13F ↗ |
| 15 | IRTC iRhythm Holdings, Inc. | 2.18M | $259.6M | 2.2% | +30.8% | 13F ↗ |
| 16 | CYTK Cytokinetics, Incorporated | 2.86M | $243.8M | 2.1% | +5.2% | 13F ↗ |
| 17 | KLRA Kailera Therapeutics, Inc. | 10.78M | $237.4M | 2.0% | New | 13F ↗ |
| 18 | ESTA Establishment Labs Holdings Inc. | 2.66M | $227.9M | 1.9% | Unchanged | 13F ↗ |
| 19 | GH Guardant Health, Inc. | 1.48M | $222.2M | 1.9% | Unchanged | 13F ↗ |
| 20 | NBIX Neurocrine Biosciences, Inc. | 1.27M | $213.7M | 1.8% | +19.4% | 13F ↗ |
| 21 | TARS Tarsus Pharmaceuticals, Inc. | 3.36M | $211.3M | 1.8% | +0.3% | 13F ↗ |
| 22 | STOK Stoke Therapeutics, Inc. | 5.62M | $184.0M | 1.6% | Unchanged | 13F ↗ |
| 23 | QURE uniQure N.V. | 3.94M | $181.5M | 1.5% | +52.4% | 13F ↗ |
| 24 | ACAD ACADIA Pharmaceuticals Inc. | 7.14M | $180.8M | 1.5% | Unchanged | 13F ↗ |
| 25 | RGEN Repligen Corporation | 1.24M | $169.3M | 1.4% | +2.9% | 13F ↗ |
| 26 | URGN UroGen Pharma Ltd. | 4.54M | $167.2M | 1.4% | Unchanged | 13F ↗ |
| 27 | GHRS GH Research PLC | 5.93M | $159.5M | 1.4% | Unchanged | 13F ↗ |
| 28 | IMCR Immunocore Holdings plc · ADR | 4.87M | $154.6M | 1.3% | Unchanged | 13F ↗ |
| 29 | CMPS COMPASS Pathways Plc · ADR | 10.70M | $151.4M | 1.3% | +0.6% | 13F ↗ |
| 30 | IMTX Immatics N.V. | 12.95M | $131.1M | 1.1% | +0.6% | 13F ↗ |
| 31 | ZLAB Zai Lab Limited · ADR | 6.57M | $124.9M | 1.1% | Unchanged | 13F ↗ |
| 32 | IMVT Immunovant, Inc. | 3.18M | $122.4M | 1.0% | Unchanged | 13F ↗ |
| 33 | BLTE Belite Bio, Inc | 715,332 | $110.2M | 0.9% | Unchanged | 13F ↗ |
| 34 | XNCR Xencor, Inc. | 6.78M | $109.1M | 0.9% | Unchanged | 13F ↗ |
| 35 | TSHA Taysha Gene Therapies, Inc. | 13.56M | $92.3M | 0.8% | -0.9% | 13F ↗ |
| 36 | COGT Cogent Biosciences, Inc. | 2.31M | $89.4M | 0.8% | -57.7% | 13F ↗ |
| 37 | ALKS Alkermes plc | 1.67M | $87.6M | 0.7% | Unchanged | 13F ↗ |
| 38 | GPCR Structure Therapeutics Inc. | 1.61M | $86.3M | 0.7% | New | 13F ↗ |
| 39 | REPL Replimune Group, Inc. | 7.41M | $82.0M | 0.7% | +0.7% | 13F ↗ |
| 40 | CSTL Castle Biosciences, Inc. | 2.78M | $66.3M | 0.6% | +0.7% | 13F ↗ |
| 41 | CADL Candel Therapeutics, Inc. | 6.42M | $66.1M | 0.6% | Unchanged | 13F ↗ |
| 42 | RCKT Rocket Pharmaceuticals, Inc. | 17.69M | $60.5M | 0.5% | Unchanged | 13F ↗ |
| 43 | KOD Kodiak Sciences Inc | 1.49M | $58.0M | 0.5% | Unchanged | 13F ↗ |
| 44 | AKTS Aktis Oncology, Inc. | 1.59M | $51.3M | 0.4% | Unchanged | 13F ↗ |
| 45 | AXGN Axogen, Inc. | 1.01M | $46.7M | 0.4% | New | 13F ↗ |
| 46 | DHR Danaher Corporation | 230,000 | $43.8M | 0.4% | New | 13F ↗ |
| 47 | CGEM Cullinan Therapeutics, Inc. | 2.36M | $43.1M | 0.4% | +38.6% | 13F ↗ |
| 48 | NGNE Neurogene Inc. | 1.36M | $42.8M | 0.4% | Unchanged | 13F ↗ |
| 49 | HNGE Hinge Health, Inc. | 500,000 | $41.5M | 0.4% | -74.1% | 13F ↗ |
| 50 | OBIO Orchestra BioMed Holdings, Inc. | 9.56M | $41.2M | 0.4% | +15.0% | 13F ↗ |
Showing the top 50 of 84 positions. Premium lists every position, plus puts and calls.
Changes since Q1 2026
9 new, 26 added to, 8 trimmed, 13 exited, 41 unchanged. By estimated dollars.
New positions (9)
| KLRA Kailera Therapeutics, Inc. | 10.78M | New | $237.4M |
| GPCR Structure Therapeutics Inc. | 1.61M | New | $86.3M |
| AXGN Axogen, Inc. | 1.01M | New | $46.7M |
| DHR Danaher Corporation | 230,000 | New | $43.8M |
| SLDB Solid Biosciences Inc. | 3.89M | New | $38.9M |
| IDYA IDEAYA Biosciences, Inc. | 370,370 | New | $13.8M |
| ALLO Allogene Therapeutics, Inc. | 3.25M | New | $6.8M |
| MAZE Maze Therapeutics, Inc. | 212,000 | New | $6.3M |
| ABVX Abivax SA · ADR | 26,400 | New | $3.5M |
Added to (26)
| RARE Ultragenyx Pharmaceutical Inc. | 7.80M | +114% | $138.5M |
| CGON CG Oncology, Inc. | 8.51M | +21.9% | $108.7M |
| ORKA Oruka Therapeutics, Inc. | 3.14M | +52.5% | $102.9M |
| QURE uniQure N.V. | 3.94M | +52.4% | $62.4M |
| IRTC iRhythm Holdings, Inc. | 2.18M | +30.8% | $61.2M |
| NBIX Neurocrine Biosciences, Inc. | 1.27M | +19.4% | $34.7M |
| RDNT RadNet, Inc. | 4.85M | +13.1% | $34.7M |
| ERAS Erasca, Inc. | 17.95M | +11.1% | $32.8M |
| CELC Celcuity Inc. | 3.30M | +8.7% | $27.8M |
| TNGX Tango Therapeutics, Inc. | 13.90M | +4.5% | $18.8M |
Trimmed (8)
| COGT Cogent Biosciences, Inc. | 2.31M | -57.7% | -$121.9M |
| HNGE Hinge Health, Inc. | 500,000 | -74.1% | -$118.7M |
| NTRA Natera, Inc. | 1.00M | -20.0% | -$67.9M |
| AVTX Avalo Therapeutics, Inc. | 175,000 | -79.6% | -$12.6M |
| BBNX Beta Bionics, Inc. | 1.50M | -25.0% | -$7.8M |
| HTFL Heartflow, Inc. | 295,000 | -40.4% | -$5.9M |
| XGN Exagen Inc. | 195,000 | -50.7% | -$931.1K |
| TSHA Taysha Gene Therapies, Inc. | 13.56M | -0.9% | -$817.1K |
Exited (13)
| Apogee Therapeutics Inc | 2.78M | Exited | -$234.2M |
| Apellis Pharmaceuticals Inc | 3.69M | Exited | -$148.2M |
| ISRG Intuitive Surgical, Inc. | 220,000 | Exited | -$101.4M |
| Centessa Pharmaceuticals plc ADR | 2.05M | Exited | -$81.6M |
| Crinetics Pharmaceuticals In | 1.45M | Exited | -$52.7M |
| WAY Waystar Holding Corp. | 1.63M | Exited | -$39.3M |
| ARWR Arrowhead Pharmaceuticals, Inc. | 585,682 | Exited | -$36.7M |
| SYK Stryker Corporation | 100,000 | Exited | -$32.9M |
| CMPX Compass Therapeutics, Inc. | 4.19M | Exited | -$22.1M |
| FLGT Fulgent Genetics, Inc. | 1.29M | Exited | -$20.5M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer